Aurinia Pharmaceuticals Inc. (AUPH) Shareholder Equity
- 2026-06-30: Additional Paid in Capital, Common StockUSD $76.19M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-977.00K; Retained Earnings (Accumulated Deficit)USD $-577.60M; Stockholders' Equity Attributable to ParentUSD $614.86M.
- 2026-03-31: Additional Paid in Capital, Common StockUSD $96.87M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-880.00K; Retained Earnings (Accumulated Deficit)USD $-615.01M; Stockholders' Equity Attributable to ParentUSD $567.63M.
- 2025-12-31: Additional Paid in Capital, Common StockUSD $111.26M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-599.00K; Retained Earnings (Accumulated Deficit)USD $-649.37M; Stockholders' Equity Attributable to ParentUSD $581.33M.
- 2025-09-30: Additional Paid in Capital, Common StockUSD $109.89M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-749.00K; Retained Earnings (Accumulated Deficit)USD $-860.16M; Stockholders' Equity Attributable to ParentUSD $365.77M.
Aurinia Pharmaceuticals Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Common Stock, Value, Outstanding USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Accumulated Other Comprehensive Income USD | Retained Earnings USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $76.19M | $-977.00K | $-577.60M | $614.86M | $1.12B | 3 month · $2.84M | (m) | (m) | (m) |
| 2026-03-31 | $96.87M | $-880.00K | $-615.01M | $567.63M | $1.09B | 3 month · $-866.00K | (m) | (m) | (m) |
| 2025-12-31 | $111.26M | $-599.00K | $-649.37M | $581.33M | $1.12B | 12 month · $14.68M | (m) | (m) | (m) |
| 2025-09-30 | $109.89M | $-749.00K | $-860.16M | $365.77M | $1.12B | 3 month · $5.92M | (m) | (m) | (m) |
| 2025-06-30 | $105.34M | $-905.00K | $-891.71M | $335.30M | $1.12B | 3 month · $5.44M | (m) | (m) | (m) |
| 2025-03-31 | $100.98M | $-825.00K | $-913.23M | $350.19M | $1.16B | 3 month · $-3.41M | (m) | (m) | (m) |
| 2024-12-31 | $127.00M | $-647.00K | $-936.57M | $377.48M | $1.19B | 12 month · $31.60M | (m) | (m) | (m) |
| 2024-09-30 | $119.77M | $-385.00K | $-938.00M | $388.00M | $1.21B | 3 month · $8.33M 9 month · $22.65M | (m) | (m) | (m) |
| 2024-06-30 | $112.27M | $-859.00K | $-952.35M | $364.62M | $1.21B | 3 month · $8.59M 6 month · $14.32M | (m) | (m) | (m) |
| 2024-03-31 | $105.42M | $-854.00K | $-953.07M | $359.48M | $1.21B | 3 month · $5.74M | (m) | (m) | (m) |
| 2023-12-31 | $120.79M | $-730.00K | $-942.32M | $377.95M | $1.20B | 12 month · $45.31M | (m) | (m) | (m) |
| 2023-09-30 | $109.71M | $-947.00K | $-915.45M | $391.88M | $1.20B | 3 month · $11.81M 9 month · $33.54M | (m) | (m) | (m) |
| 2023-06-30 | $98.83M | $-1.02M | $-902.00M | $392.29M | $1.20B | 3 month · $12.27M 6 month · $21.73M | (m) | (m) | (m) |
| 2023-03-31 | $88.89M | $-988.00K | $-890.51M | $390.41M | $1.19B | 3 month · $9.47M | (m) | (m) | (m) |
| 2022-12-31 | $85.49M | $-1.06M | $-864.30M | $405.44M | $1.19B | 12 month · $32.30M | (m) | (m) | (m) |
| 2022-09-30 | $79.19M | $-1.53M | $-838.26M | $423.43M | $1.18B | 3 month · $8.32M 9 month · $25.40M | (m) | (m) | (m) |
| 2022-06-30 | $74.00M | $-1.85M | $-829.27M | $423.77M | $1.18B | 3 month · $10.05M 6 month · $17.08M | (m) | (m) | (m) |
| 2022-03-31 | $64.69M | $-1.62M | $-793.75M | $448.12M | $1.18B | 3 month · $7.02M | (m) | (m) | (m) |
| 2021-12-31 | $59.01M | $-852.00K | $-756.12M | $479.09M | $1.18B | 12 month · $31.24M | (m) | (m) | (m) |
| 2021-09-30 | $54.61M | $-794.00K | $-722.80M | $298.17M | $967.16M | 3 month · $7.09M 9 month · $22.67M | (m) | (m) | (m) |
| 2021-06-30 | $51.02M | $-792.00K | $-672.54M | $332.26M | $954.57M | 3 month · $7.75M 6 month · $15.57M | (m) | (m) | (m) |
| 2021-03-31 | $43.89M | $-799.00K | $-625.53M | $370.23M | $952.67M | 3 month · $7.82M | (m) | (m) | (m) |
| 2020-12-31 | $39.38M | $-805.00K | $-575.16M | $407.75M | $944.33M | 12 month · $17.45M | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | $409.44M | (m) | 3 month · $4.61M 9 month · $12.31M | 3 month · $12.27M 9 month · $12.27M | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | $257.70M | (m) | 3 month · $4.20M 6 month · $7.70M | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | $279.09M | (m) | 3 month · $3.50M | (m) | (m) | (m) |
| 2019-12-31 | $25.39M | $-805.00K | $-472.48M | $298.60M | $746.49M | 12 month · $7.41M | (m) | $-805.00K | $-539.81M |
| 2018-12-31 | (m) | (m) | (m) | $135.72M | (m) | 12 month · $6.86M | (m) | $-805.00K | $-415.96M |
| 2017-12-31 | (m) | (m) | (m) | $177.92M | (m) | (m) | (m) | $-883.00K | $-351.84M |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-805.00K | $-281.05M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |